VRCA:NASDAQVerrica Pharmaceuticals Inc. Analysis
Data as of 2026-09-01 - not real-time
$5.46
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Verrica Pharmaceuticals Inc. trades at $5.46, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. RSI sits at 55.4, which reads as neutral, and MACD momentum is bullish. Watch $4.61 as support and $5.87 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 171.1% above the current price. Revenue is contracting at 53.9% on a -102.8% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 65.3%, a beta of 2.07 and a maximum drawdown of 51.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to sell, carrying 4/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 171.1% above the current price. Revenue is contracting at 53.9% on a -102.8% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 65.3%, a beta of 2.07 and a maximum drawdown of 51.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to sell, carrying 4/10 conviction.
Top Market Events
Verrica Pharmaceuticals Inc. VRCA came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate...WEST CHESTER, Pa., July 30, 2026 GLOBE NEWSWIRE -- Verrica Pharmaceuticals Inc. “Verrica” or “the Company”...Yahoo Finance24dVerrica Pharmaceuticals Q2 Earnings Call HighlightsVerrica Pharmaceuticals NASDAQ:VRCA reported...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 6.23
- MACD momentum is positive
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 6.23
- Analyst targets imply +171.1% versus the current price
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Negative profit margin of -102.8%
- Analyst targets imply +171.1% versus the current price
- Revenue contracting at -53.9%
Key Metrics & Analysis
Financial Health
Revenue Growth-53.90%
Profit Margin-102.84%
P/E Ratio-3.7
ROA-43.98%
Debt/Equity42.02
P/B Ratio21.8
Op. Cash Flow$-13347000
Free Cash Flow$-9037125
Industry P/E30.4
Technical Analysis
TrendBearish
RSI55.4
Support$4.61
Resistance$5.87
MA 20$5.09
MA 50$5.51
MA 200$6.23
MACDBullish
VolumeIncreasing
Fear & Greed Index94.79
Valuation
Target Price$14.80
Upside/Downside171.06%
GradeFair
TypeBlend
Risk Assessment
Beta2.07
Volatility65.35%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.